Serum IL-6 and TNF-α in Type 1 Diabetes Mellitus Patients in Mosul

  • Sura M. Y. Al-Taee Department of Biology, College of Sciences, Mosul University, Mosul-Iraq.
  • Adeeba Y. S. Al-Noaman Department of Biology, College of Sciences, Mosul University, Mosul-Iraq.
Keywords: Type 1 Diabetes Mellitus, IL-6, TNF—α.


The objective of the study is to evaluate the levels of IL-6 and TNF-α in sera of patients with type 1 diabetes mellitus (T1DM) compared to healthy people and correlate their levels with different factors. The results showed significant increase in the levels of IL-6 and TNF-α (P≤0.05) in T1DM compared to control group. The levels of IL-6 were not significant when compared with age groups, duration of the disease and level of HbA1c. On contrast the levels of TNF-α in T1DM patients was significantly increased (P≤0.05) when compared with age groups and duration of the disease but not significantly with different HbA1c.


Ferreira-Hermosillo A, Molina-Ayala M , Ramírez-Rentería C , Vargas G1, Gonzalez B, Isibasi A , et al.. Inflammatory Cytokine Profile Associated with Metabolic Syndrome in Adult Patients with Type 1 Diabetes. J Diabetes Res. 2015;2015:972073.

Alnek K, Kisand K, Heilman K, Peet A, Varik K, Uibo R (2015) Increased Blood Levels of Growth Factors, Proinflammatory Cytokines, and Th17 Cytokines in Patients with Newly Diagnosed Type 1 Diabetes. PLoS ONE 10(12): e0142976.

International Diabetic Federation. IDF diabetes atlas 7th ed. Brussels: International Diabetic Federation; 2015.

Eizirik DL, Sandler S, Welsh N, Cetkovic-Cvrlje M, Nieman A, Geller D A, et al.. Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. J Clin Invest. 1994 May; 93(5): 1968–1974.

Peraldi P, Spiegelman B. TNF-α and insulin resistance: Summary and future prospects. Molecular and Cellular Biochemistry, 1998, 182(1-2): 169-175.

Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. 1999;353(9165):1649-1652.

Erbağci AB, Tarakçioğlu M, Coşkun Y, Sivasli E, Namiduru ES. Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children. Clinical Biochemistry 2001;34(8):645-650.

Ozer G, Teker Z, Cetiner S, Yilmaz M, Topaloglu AK, Onenli-Mungan N, et al. Serum IL-1, IL-2, TNFalpha and INFgamma levels of patients with type 1 diabetes mellitus and their siblings. Journal of Pediatric Endocrinology and Metabolism 2003;16(2):203-210.

Davì G, , Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A, et al. Enhanced Lipid Peroxidation and Platelet Activation in the Early Phase of Type 1 Diabetes Mellitus: Role of Interleukin-6 and Disease Duration . Circulation 2003;107(25):3199-3203.

Febbraio MA, Hiscock N, Sacchetti M, Fischer CP, Pedersen BK. Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction. Diabetes. 2004;53(7):1643-1648.

Pal M, Febbraio MA, Whitham M. From cytokine to myokine: the emerging role of interleukin-6 in metabolic regulation. Immunol Cell Biol. 2014 ;92(4):331-339.

Glund S, Deshmukh A, Long YC, Moller T, Koistinen HA, et al. Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes. 2007;56(6):1630-1637.

Nieto-Vazquez I, Fernández-Veledo S, de Alvaro C, Lorenzo M. Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes. 2008;57(12):3211-3221.

Ellingsgaard H, Hauselmann I, Schuler B, Habib AM, Baggio LL, Meier DT, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med. 2011;17(11):1481-1489.

Suzuki T, Imai J, Yamada T, Ishigaki Y, Kaneko K, Uno K, et al. Interleukin-6 enhances glucose-stimulated insulin secretion from pancreatic beta-cells: potential involvement of the PLC-IP3-dependent pathway. Diabetes. 201;60(2):537-547.

Karavanaki K1, Kakleas K, Georga S, Bartzeliotou A, Mavropoulos G, Tsouvalas M, et al. Plasma high sensitivity C-reactive protein and its relationship with cytokine levels in children with newly diagnosed type 1 diabetes and ketoacidosis. Clin Biochem. 2012;45(16-17):1383-1388.

Chen YL, Qiao YC2, Pan YH, Xu Y, Huang YC, Wang YH1, Geng LJ, et al. Correlation between serum interleukin-6 level and type 1 diabetes mellitus: A systematic review and meta-analysis. Cytokine. 2017;94:14-20.

Huang W, Wang DS, Li XY, Wu WZ,Ni GC. Expression of levels of IL-6 mRNA in PBMNCs from patients with IDDM and normal by RT-PCR procedure. Clin Chinese Med J. 1993;106(12):893-897.

Kulseng B, Skjåk-Braek G, Følling I, Espevik T. TNF production from peripheral blood mononuclear cells in diabetic patients after stimulation with alginate and lipopolysaccharide. Scand J Immunol. 1996;43(3):335-340.

Geerlings SE, Brouwer EC, Van Kessel KC, Gaastra W, Stolk RP, Hoepelman AI. Cytokine secretion is impaired in women with diabetes mellitus. Eur J Clin Invest. 2000;30(11):995-1001.

Hammed IK, Rashid NF, Abed NA. Serum interleukin-6 level in children with type 1 diabetes mellitus. J Fac Med Baghdad. 2012;54(3):228-230.

Kavitha G, Ramani G, Priya KD, Aruna RM. Oxidative stress, IL-6 and atherogenic index of plasma in diabetic nephropathy. J Appl Biol Pharm Technol . 2011;2(2)211-217.

Foss-Freitas MC, Foss NT, Donadi EA, Foss MC. Effect of the glycemic control on intracellular cytokine production from peripheral blood mononuclear cells of type 1 and type 2 diabetic patients. Diabetes Research and Clinical Practice 2008; 82,(3):329–334.

Qiao YC, Chen YL, Pan YH, Tian F, Xu Y, Zhang XX, et al. The change of serum tumor necrosis factor alpha in patients with type 1 diabetes mellitus: A systematic review and meta-analysis. PLoS One. 2017;12(4):e0176157.

Zier KS, Leo MM, Spielman RS, Baker L. Decreased synthesis of interleukin-2 (IL-2) in insulin-dependent diabetes mellitus. Diabetes. 1984;33(6):552-5.

Netea MG, Hancu N, Blok WL, Grigorescu-Sido P, Popa L, Popa V, et al. Interleukin 1 beta, tumour necrosis factor-alpha and interleukin 1 receptor antagonist in newly diagnosed insulin-dependent diabetes mellitus: comparison to long-standing diabetes and healthy individuals. Cytokine. 1997 Apr;9(4):284-287.